Early Human Feasibility Experience with a Novel Transcatheter Cardiac Leaflet Enhancer (CARLEN) to Treat Functional Mitral Regurgitation in Heart Failure reduced Ejection Fraction

<p>Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: </p><ul><li>Consultant Fee/Honoraria/Speaker's Bureau - Edwards Lifesciences; GE Healthcare; Medtronic; Valgen; Neochord; Shifamed; Abbott; Nyra; Meacor; Philips; Biosense Webster; Cardiawave; Tomoverse</li><li>Equity/Stock(s)/Options - Tioga; Meacor; Trajectory; Cardiawave</li></ul>